This is a 12-week open-label extension study for participants completing study NCT06221852.
Age range
18 Years – 45 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Change in brain redox nicotinamide adenine dinucleotide metabolites ratio (NAD+/NADH)
Timeframe: 24 weeks
Change in brain creatine kinase forward reaction rate (kf)
Timeframe: 24 weeks
Change in insulin resistance
Timeframe: 24 weeks
Change in psychotic symptoms
Timeframe: 24 weeks
Change in depressive symptoms
Timeframe: 24 weeks
Change in mania symptoms
Timeframe: 24 weeks
Change in Clinical Global Impression (CGI) Scale
Timeframe: 24 weeks